Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in Myeloma
Open Access
- 26 May 2023
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (8) , 504.e1-504.e7
Abstract
No abstract availableKeywords
Funding Information
- University of California
This publication has 33 references indexed in Scilit:
- A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myelomaBlood, 2021
- Modified Hyper-CVAD With Proteasome Inhibition for Multiple Myeloma: A Single-Center Retrospective AnalysisClinical Lymphoma Myeloma and Leukemia, 2020
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myelomaLeukemia & Lymphoma, 2018
- High-Dose Cyclophosphamide in Highly Refractory Multiple Myeloma Patients As a Bridge to Further Novel TherapiesBlood, 2016
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working GroupBlood, 2016
- Serum Free Light Chain Assessment Early After Stem Cell Transplantation as a Prognostic Factor in Multiple MyelomaClinical Lymphoma Myeloma and Leukemia, 2015
- Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPREuropean Journal of Haematology, 2014
- Appraisal of immunoglobulin free light chain as a marker of responseBlood, 2008
- The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chainsLeukemia & Lymphoma, 2006